




**cassderma**<sub>Rx</sub>


---

HEALING SKIN AND WOUNDS FASTER –  
ALLOWING PATIENTS TO GET BACK TO LIVING LIFE SOONER!

# Executive Summary



20 Million Americans annually need of Wound Healing care



Over \$10 Billion per year are spent on Wound Healing in US alone



New therapeutics are necessary for more effective Wound Healing, unmet need



Serum-free nutrient rich medium supplemented with a non-steroidal anabolic hormone to successfully treat atrophic recalcitrant wounds



cassderma rx granted patent with multiple allowances on a formulation and methods for stimulating wound healing

## Stimulated Healing of Recalcitrant Wounds by Topical Application of Enriched Cell Culture Medium: A Clinical Report

Ella S. Lindenbaum, Ph.D., Yaron Har Shai, M.D., Yehuda Ullmann, M.D., Lev A. Feitelberg, M.D., Dvora Beach, M.Sc., Aviva Gamliel-Lazarovich, M.Sc., and Bernard Hirshowitz, M.D.

*Haiifa, Israel*

# Cassderma Management Team

DANIEL NAVID RASTEIN, MD, MPH

FOUNDER & CEO



MONIL SHAH, PHARM.D, MBA

CLINICAL DEVELOPMENT



NOVARTIS

AMGEN



Bristol-Myers Squibb



Brooklyn



WindMIL

KIP VOUGHT

DEVELOPMENT &  
REGULATORY AFFAIRS



MIKE SWEETING

COMMERCIALIZATION &  
MARKET ACCESS



HERB BRINKMAN

MANUFACTURING



OTHER PARTNERS:

K & L GATES GLOBAL LEGAL; TKL DERMATOLOGY RESEARCH LABORATORIES

# Current Treatments Options are Insufficient

## Wound and Skin Injuries

Burns	Closed Surgical Wounds	Deep Tissue Pressure Injury	Diabetic Foot Ulcers
Incontinence associated dermatitis	Leg Ulcers	Moisture Associated Skin Damage	Medical Adhesive Related Skin Damage
Medical Device Related Pressure Injuries	Open Surgical Wounds	Skin Tear	Stage 3 & 4 Pressure Injury
	Trauma	Unstageable Pressure Injury	


## Treatment Options

- Antimicrobial dressing
- Cleansers
- Compression bandage
- Filler
- Alginate dressing
- Foam Dressing
- Hydrocolloid
- Hydrofiber® Technology
- Hydrogel
- Primary dressing
- Secondary dressing (cover)
- Surgical Cover Dressing

# cassderma rx Technology

---

- Formulation containing serum-free cell culture nutrient medium supplemented with a non-steroidal anabolic hormone to successfully treat atrophic recalcitrant wounds.
- Human cell culture technology of growing fibroblast and epithelial cells in culture.
- Utilizing similar nutrient media supplements with insulin or substances possessing insulin-mimetic features.
- Milieu in the wound becomes moist and enriched with the nutrients required for cells proliferation and the growth of the granulation tissue into the wound space.
- Stimulates and supports growth of connective tissue components originating from the wound bed and its peripheral walls.
- Granulation tissue filling the wound space will create the substratum required for re-epithelialization and wound closure.
  
- Prescription and/or OTC option



# cassderma rx Used for Healing All Types of Wounds

## Surgical



FIG. 4. (Left) One week after surgical amputation of the first left toe because of gangrene in a diabetes mellitus patient. (Right) Complete wound closure following 9 weeks of treatment with enriched cell culture medium.

## Diabetic Ulcers




FIG. 7. (Left) A deep atrophic ulcer of 14 months duration on the lateral aspect of the left heel in an insulin-dependent neuropathic patient suffering from diabetes mellitus. (Right) Complete wound closure was achieved after 5 months of treatment with enriched cell culture medium. Follow-up after 1 year showed that the wound remained closed.

## Burns



FIG. 6. (Left) A bilateral neuropathic second- and third-degree burn of the metatarsal areas in a diabetes mellitus patient. (Right) Complete healing of the burns was accomplished in 6 weeks of treatment with enriched cell culture medium. Note the absence of scarring and the smooth skin in the affected areas.

## Pressure Ulcers






FIG. 8. (Left) A chronic atrophic and pressure ulcer of 12 years duration, on the metatarsal surface of the left foot in a patient with non-insulin-dependent diabetes mellitus. (Right) Treatment with enriched cell culture medium lasted 4 months when complete wound closure was attained.

# Competition



# Investment Opportunity



## THE OFFER

\$5M Raise  
Convertible Note  
20% Discount Series A

2021



## USE OF FUNDS

GMP Manufacturing  
Nonclinical Development  
Regulatory  
Clinical Development

2021 - 2022



## EXIT STRATEGY

Strategic Partnership  
Acquisition or Out-Licensing  
IPO

2024



**DANIEL NAVID RASTEIN, MD, MPH  
CEO & FOUNDER**

*“Nothing exists in the world to stimulate wounds to heal faster – until now. In diabetes patients alone, 84% of amputations are attributed to open wounds. Historically, the only treatment is to clean, disinfect, change bandages and repeat. This is a futile cycle and millions of patients are suffering. We are here to help”*

